Tikcro Technologies Reports 2011 Second Quarter Results

TEL AVIV, Israel--(BUSINESS WIRE)-- Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the second quarter and six months ended June 30, 2011.

Net loss for the second quarter was $1.5 million or $(0.17) per diluted share. Results for the second quarter included financial expenses of approximately $1.3 million that resulted from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Excluding this non cash financial expense, net loss for the second quarter was $134,000 or $(0.02) per diluted share. Net loss for the six months ended June 30, 2011 was $1.5 million or $(0.15) per diluted share. Results for the six months ended June 30, 2011 included a financial expense of approximately $1.4 million from the valuation of Tikcro holdings in BioCancell Therapeutics, Inc. Excluding this non cash financial expense, net loss for the six months ended June 30, 2011 was $143,000 or $(0.02) per diluted share.

Tikcro holds approximately 26% of BioCancell, taking into account the conversion of a convertible note and an exercising of warrants. On a fully diluted basis Tickro holds approximately 17% of BioCancell. Shares of BioCancell are traded on the Tel Aviv Stock Exchange (TASE). The valuation of the holding in BioCancell is influenced, among other factors, by the share price of BioCancell on TASE.

BioCancell is a clinical stage biotechnology company focused on developing targeted cancer therapies for solid cancer tumors. The Company’s lead drug-candidate, BC-819, is progressing toward a US FDA Phase IIb clinical trial for pancreatic cancer. The Phase IIb clinical trial follows recently published one-year, multi-center Phase I/IIa results, addressing patients with non-resectable (inoperable) pancreatic cancer, with no metastases.

Following three months of treatment with BC-819 in the Phase I/IIa trial, five out of nine patients showed significant tumor reduction or stability, and two out of six patients in the higher dosage group became resectable (operable).

Approximately 80% of patients with pancreatic cancer die within a year of diagnosis and 95% within five years. BC-819 uses the H19 gene to synthesize Diphtheria Toxin in cancerous cells only, in order to destroy the cells. BC-819 is also undergoing Phase IIb trial for bladder cancer and Phase I/IIa trial for ovarian cancer.

As of June 30, 2011, the Company had net cash and marketable securities totaling $7.2 million.

About Tikcro Technologies:

Tikcro has holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. BioCancell's leading drug, BC-819, is a double stranded DNA plasmid construct that incorporates the gene for diphtheria toxin (DTA) under the regulation of the promoter sequence for H19 gene. Pursuant to U.S. FDA approved protocols, BioCancell concluded a phase I/IIa clinical trial for the treatment of pancreatic cancer and is conducting a phase IIb clinical trial for the treatment of superficial bladder carcinoma cancer and a

Phase I/IIa clinical trial for the treatment of ovarian cancer.

For more information, visit Tikcro website at www.tikcro.com.

Safe Harbor Statement

Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the business of BioCancell, including, but not limited to, the development, testing, regulatory approval and commercialization of its products, its intellectual property rights, its funding, its competition, its exposure to lawsuits and its dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Form 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. We undertake no duty to update any forward-looking information.

Tikcro Technologies Ltd.

Balance Sheet

(US dollars in thousands)

       

June 30, 2011

December 31, 2010
Assets
Current assets
Cash and short-term marketable securities $ 7,243 $ 7,308
Other receivables   169   118
Total current assets 7,412 7,426
 
Investment in BioCancell – stock, convertible note and warrant 4,274 5,625
 
Total assets $ 11,686 $ 13,051
 
Liabilities and Shareholders' Equity
Current liabilities
Other current liabilities $ 447 $ 318
 
Shareholders' equity   11,239   12,733
 
Total liabilities and shareholders' equity $ 11,686 $ 13,051
       
Tikcro Technologies Ltd.

Statement of Operations

(US dollars in thousands, except per share data)

 
 
Three Months Ended June 30, Six Months Ended June 30,
2011 2010 2011 2010
General and administrative expenses $ 219   $ 79   $300   $ 150  
 
Total operating expenses   219     79   300     150  
 
Operating loss (219 ) (79 ) (300 ) (150 )
 
Financial income (expenses), net   (1,223 )   (3,143 ) (1,172 )   (1,137 )
 
Tax expenses   (22 )   -   (22 )   -  
 
Net income (loss) $ (1,464 ) $ (3,222 ) $(1,494 ) $ (1,287 )
 
Basic net earnings (loss) per share $ (0.17 ) $ (0.38 ) $(0.17 ) $ (0.15 )
 
Diluted net earnings (loss) per share $ (0.17 ) $ (0.38 ) $(0.17 ) $ (0.15 )
 
Basic weighted average shares   8,556     8,460   8,550     8,445  
 
Diluted weighted average shares   8,556     8,460   8,550     8,445  



CONTACT:

Investor Relations:
KCSA Strategic Communications
Jeff Corbin / Adam Pollack
212-896-1214 / 1232
[email protected] / [email protected]

KEYWORDS:   United States  North America  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Professional Services  Banking  Finance  General Health

MEDIA:

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.